Pictet Asset Management Holding SA Sells 110,241 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Pictet Asset Management Holding SA cut its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 6.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,517,636 shares of the biopharmaceutical company's stock after selling 110,241 shares during the period. Pictet Asset Management Holding SA owned about 0.51% of Amicus Therapeutics worth $14,296,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of FOLD. Norges Bank bought a new stake in Amicus Therapeutics in the 4th quarter valued at $29,033,000. Wellington Management Group LLP raised its position in Amicus Therapeutics by 13.5% in the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock worth $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Amicus Therapeutics during the third quarter worth about $13,530,000. Vanguard Group Inc. boosted its holdings in Amicus Therapeutics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock valued at $275,619,000 after purchasing an additional 458,143 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its stake in shares of Amicus Therapeutics by 41.0% in the 4th quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company's stock valued at $12,916,000 after purchasing an additional 398,942 shares during the period.

Analysts Set New Price Targets

Several analysts recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Wells Fargo & Company decreased their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Finally, Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $16.75.

Amicus Therapeutics Price Performance

Shares of FOLD stock traded down $0.50 during trading hours on Friday, reaching $7.50. 3,184,754 shares of the company were exchanged, compared to its average volume of 2,535,352. Amicus Therapeutics, Inc. has a fifty-two week low of $7.39 and a fifty-two week high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The stock's fifty day moving average is $9.12 and its two-hundred day moving average is $9.84. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -41.67, a P/E/G ratio of 1.51 and a beta of 0.79.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.